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Lipopeptides: from self-assembly to bioactivity
Ian W. Hamley*
This Feature Article discusses several classes of lipopeptide with important biomedical applications as
antimicrobial and antifungal agents, in immune therapies and in personal care applications among
others. Two main classes of lipopeptide are considered: (i) bacterially-expressed lipopeptides with a
cyclic peptide headgroup and (ii) linear lipopeptides (with one or more lipid chains) based on bio-
derived and bio-inspired amino acid sequences with current clinical applications. The applications are
briefly summarized, and the biophysical characterization of the molecules is reviewed, with a particular
focus on self-assembly. For several of these types of biomolecule, the formation of micelles above a
critical micelle concentration has been observed while others form bilayer structures, depending on
conditions of pH and temperature. As yet, there are few studies on the possible relationship between
self-assembly into structures such as micelles and bioactivity of this class of molecule although this is
likely to attract further attention.
Introduction
Lipopeptides are a remarkable class of self-assembling molecule
that are able to form peptide-functionalized supramolecular
nanostructures. Lipopeptides are amphiphilic molecules which
incorporate one or more lipid chains attached to a peptide head-
group. Self-assembly is observed depending on the hydrophile/
lipophile balance of the molecules as well as interactions between
the peptide units. The self-assembly of synthetic bio-mimetic and
bio-inspired lipopeptides has been the subject of previous reviews
and this is not covered again here.1 We present an up-to-date
overview on the self-assembly of bio-derived and bio-active lipo-
peptides, with proven activity in on-the-market applications in
medicine and other fields such as crop protection.
Compared to the self-assembly of lipids, that of lipopeptides
is relatively unexplored. This is remarkable, given their relevance
to important applications in biomedicine, including use as last
resort antimicrobial agents to treat for example MRSA (methicillin-
resistant S. aureus) infections (e.g. daptomycin, Fig. 1),2 use in
immune disease therapies (e.g. Pam3CSK4, Fig. 13)
3 and in
cosmeceuticals (e.g.Matrixylt, C16-KTTKS).
4 Other applications
of lipopeptides extend beyond human medicine, including use
as fungicides for crop treatment (e.g. surfactin, Fig. 7b),5 avoiding
adverse environmental eﬀects associated with a conventional
synthetic pesticides.5b,6 For potential biomedical applications,
lipopeptides oﬀer advantages compared to peptides of improved
amphiphilicity and compatibility with the lipid wall of cell
membranes, enabling for example the delivery of actives into
cells via endocytosis (vide infra). In addition, the self-assembly of
lipopeptides facilitates the presentation of peptide functionalities
at high density on the surface of nanostructures such as fibrils,
micelles and vesicles.
In the main, naturally expressed bioactive lipopeptides con-
tain a cyclic peptide headgroup attached to a single lipid chain.
Cyclisation of the peptide unit as in many bacterially expressed
lipopeptides enhances the in vivo stability of the motif
compared to the linear counterpart (and thus can be expected
to have evolved to be expressed in the cyclic form). This is due
to reduced proteolysis resulting from the absence of free C- and
N-termini.7 Of course, cyclisation also restricts the peptide
conformation which may also be relevant to bioactivity. Expressed
lipopeptides usually comprise molecules with a range of lipid
chain lengths (typically in the range C14–C18) and conformations.
Another class of bioactive lipopeptides is usually produced synthe-
tically based on bio-derived sequences. These lipopeptides often
contain a linear peptide headgroup attached to one, two or three
Fig. 1 Molecular structure of daptomycin.11
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hexadecyl (palmitoyl) lipid chains. In the following we use the
notation C16 or Pam for a hexadecyl lipid chain, depending on
conventional usage for the relevant lipopeptide.
This review is focussed on lipopeptides, and does not cover
the fascinating field of lipoproteins which also have a variety of
in vivo biological roles, for example apolipoproteins are the
major component of high density lipoproteins which are a risk
factor associated with cardiovascular disease. The structure
of apolipoproteins has been reviewed elsewhere.8 This is a
mini-review aiming to introduce the main classes of bioactive
lipopeptides investigated to date, relating their structure to
activity and self-assembly properties where these have been
investigated (which is only the case for a few materials). It is not
our purpose to exhaustively review all studies on the biological
activity of lipopeptides, of which there are many hundreds
published. We apologise to the authors of papers whose work
has not been included.
Previous reviews have been published covering lipopeptides
as a class of biosurfactant.9 In addition, reviews focussed
specifically on the natural functions of lipopeptides from
Bacillus and Pseudomonas species are available.6b,10
As discussed in the following, lipopeptides may self-assemble
into spherical micelles above a critical micelle concentration
(cmc) or into other structures (especially nanofibrils and nano-
tapes), in which case we use the notation critical aggregation
concentration (cac) to denote the concentration above which self-
assembly is observed.
Bacterially expressed cyclic
lipopeptides
Lipopeptides are expressed by many bacteria, having several
roles including activity against other microorganisms including
bacteria, fungi and viruses, involvement in bacterial motility
and swarming behaviour and in attachment to surfaces.6b,10e
The host defensemechanism produces lipopeptides in response to
other microorganisms including fungi, viruses, mycoplasma and
bacteria. Two genera of bacteria, Bacillus and Pseudomonas have
produced lipopeptides that have been particularly extensively
studied. They have important applications due to antibacterial,
antifungal and antiviral activity as discussed in the following.
Daptomycin (Fig. 1) is a lipopeptide comprising a decanoyl
lipid chain attached to a partly cyclised 13-amino acid peptide.
Daptomycin is produced by the Gram-positive bacterium
Streptomyces roseoporous.12 It has potent antimicrobial proper-
ties and is clinically approved for use as an antibiotic for
serious infections caused by Gram-positive bacteria such as MRSA
(methicillin-resistant Staphylococcus aureus) and vancomycin-
resistant enterococci.12a It is marketed under the tradename Cubicin
by Cubist Pharmaceuticals2c,13 (recently acquired by Merck). It
incorporates two non-natural amino acids: L-kynurenine, which
is unique to daptomycin, and L-3-methylglutamic acid. The former
residue, containing an aniline unit, gives rise to interesting
fluorescence properties, in particular an emission peak at
460 nm.14 The mode of activity of daptomycin is still unclear.12a,15
One hypothesis involves the inhibition of lipoteichoic acid synthe-
sis (lipoteichoic acid is a proteoglycan which is a major compo-
nent of the cell wall of Gram-positive bacteria).15 Another
proposed mechanism involves disruption of bacterial membrane
potential, for example via pore formation.15 The latter mechanism
seems favoured based on recent work examining ion-dependent
pore formation inmodel membranes,16 along with the fact that its
activity is calcium ion dependent.17
The existence of a critical aggregation concentration (cac)
has been determined for daptomycin by making use of the
afore-mentioned fluorescence properties of the lipopeptide, as
well as NMR and light scattering techniques.14b The cac has
been measured as a function of pH, temperature and calcium
ion concentration.14b The aggregation number in aqueous
solution at pH 4–6.5 is reported as (18  2). Fig. 2 shows a
cryo-TEM recently obtained by our group showing spherical
micelles formed by daptomycin.
The echinocandins are a class of cyclic lipopeptide compounds
with antifungal activity. Examples of this class of molecule are
shown in Fig. 3. The most widely known is caspofungin, marketed
as a drug by Merck and Co. The antifungal activity of this class of
compound is due to the interaction of lipopeptide molecules with
the insoluble polysaccharide component of the cell wall of fungal
cells, specifically due to the inhibition of the synthesis of
glucans.19 The interactions of echinocandins with Candida fungi
such as C. albicans has been particularly well studied.19,20 The self-
assembly properties of these compounds seem to be largely
unexamined although Eli Lilly have patented micellar formula-
tions of echinocandins with conventional surfactants.21
Viscosin (Fig. 4) is a cyclic lipopeptide obtained from
Pseudomonas libanensis23 or Pseudomonas fluorescens.22 It has
antibiotic activity as shown against the tubercle bacillus.24
Viscosin is highly surface active23a,25 and is able to inhibit the
migration of cancer cells.23b Fig. 5 shows surface tension data
used to determined a cmc = 0.15 mg ml1 for viscosin in
aqueous solution. Viscosin and the related cyclic lipopeptide
massetolide (Fig. 4) also produced by P. fluorescens are able to
protect it from protozoan predation.22
Lichenysins,27 pumilacidins28 and polymyxin B (Fig. 6)29 are
classes of antimicrobial lipopeptides produced by Bacillus
Fig. 2 Cryo-TEM image of micelles formed by daptomycin (2.5 mM in
0.625 mM CaCl2).
18
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licheniformis, Bacillus pumilus and Bacillus polymyxa respec-
tively. Lichenysin A (Fig. 7a) is a powerful surfactant, and
antimicrobial activity against several Gram positive and Gram
negative bacteria, although not as great as that observed
for surfactin.27a Several pumilacidins show antiviral activity
against herpes simplex virus as well as anti-ulcer activity.28
Polymyxin B (Fig. 6) and polymyxin E (colistin) show antibiotic
activity against a range of Gram-negative bacteria.29 The two
molecules are distinguished by the substitution of a D-leucine
in colistin with a D-phenylalanine in polymyxin B.26b The mode
of action of these lipopeptides has been proposed to be
membrane disruption due to interaction between the cationic
polymyxin and the anionic bacterial outer membrane leading to
a detergent-like activity.29
Fig. 7 shows the structure of several lipopeptides produced
by B. subtilis.30 Variants of surfactins, iturins and lichenysins
can be genetically engineered to incorporate diﬀerent amino
acids (via for example, incorporation in the bacterial culture
medium). Synthetic variants have also been examined. The
engineered/synthetic Bacillus lipopeptides have distinct struc-
ture–activity relationships as reviewed elsewhere.5a,b,10b All of
these classes of lipopeptide are potent antifungal agents with
applications in crop protection.6a,31 The effect of surfactin on
the swarming behaviour of B. subtilis has been examined,
its absence reducing swarming activity.32
Cyclic lipopeptides produced by Pseudomonas species include
the viscosin group (as discussed above), the amphisin group,
the syringomycin group and the tolaasin group (Fig. 8).10e,33 The
biosynthesis of these lipopeptides is discussed elsewhere.10e
There are few studies on the aggregation behaviour of these
lipopeptides although a report on the biosurfactant and ion-
channel forming properties of two lipopeptides from the syrin-
gomycin group is available.34 This includes a cmc measurement
of 0.8 mg ml1 for both syringomycin and syringopeptin from a
Pseudomonas syringae strain. Calcium ion channel formation was
observed at nanomolar concentrations showing the cytotoxicity of
these lipopeptides to plant cells.34
Surfactin is a highly surface-active biosurfactant reducing
the surface tension of water to 27 mN m1 at a concentration
as low as 20 mM.10b The cmc at room temperature is 7.5 mM.
Fig. 3 Molecular structure of several echinocandins. Adapted from ref. 19.
(a) Caspofungin, (b) micafungin, (c) anidulafungin.
Fig. 4 Viscosin (R = H) and massetolide (R = CH3).
22
Fig. 5 Surface tension versus concentration used to determine the cmc
for viscosin (shown by arrow). Redrawn from ref. 23a.
Fig. 6 Structure of polymyxin B.26 Polymyxin B is a mixture of lipopeptides
with diﬀerent lipid chain lengths (here indicated by R).
Fig. 7 Structure of some lipopeptides produced by B. subtilis. (a) Surfactin
(b) lichenysin A, (c) iturin A, (d) fengycin/plipastatin A. Redrawn from ref. 5b.
As detailed in ref. 5b, the expressed lipopeptides actually comprise a mixture
of lipid chain lengths.
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The temperature dependence of the cmc has been examined,
along with the thermodynamic parameters of micellization, via
isothermal titration calorimetry.38 The cmc of surfactin is very
low compared to that of many surfactants such as non-ionic
surfactants of the CnEOm class where EO denotes ethylene oxide
and the subscripts are the number of repeats. This is shown
in Fig. 9 which plots the water/phospholipid bilayer partition
coeﬃcient against cmc.38 The partition coeﬃcient, K, was
analysed as part of a study on membrane permeabilization.
There is also a relationship between the surfactant-to-lipid
mole ratio at the onset of solubilisation and K  cmc.38
The aggregation of surfactin (Fig. 7a) in bulk solution and at
air/water and hydrophobic solid/water interfaces was investi-
gated using neutron scattering techniques.39 Small-angle neutron
scattering indicated the presence of small (association number
p = 20) spherical micelles in bulk aqueous solution whilst at the
interface (either air/water or silane/water) surfactin was found to
adopt a globular conformation.39 Neutron reflectometry was
also used to probe the interaction between surfactin and solid-
supported phospholipid bilayers – below the cmc of surfactin a
mixed bilayer was reported.40 Later, as part of a study also
including other Bacillus subtilis lipopeptides, the self-assembly
of surfactin in aqueous solution was investigated via cryogenic
transmission electron microscopy (cryo-TEM) and small-angle
X-ray scattering (SAXS), and the secondary structure was probed
using circular dichroism (CD) and FTIR spectroscopic methods.30
Cryo-TEM and SAXS revealed spherical micelles with a radius of
2.0 nm, consistent with the findings of Shen et al.39 but contra-
dictory to the report of Ishigami et al.41 who reported large
rod-shaped micelles, albeit in a different buffer (NaHCO3). CD
and FTIR were consistent with random coil and turn structures
for surfactin (again contrary to Ishigami et al. who reported
b-sheet secondary structure41). Similar findings in regard to self-
assembled nanostructure and secondary structure were noted for
plipastatin (Fig. 7d). Unexpectedly, and in complete constrast to
surfactin and plipastatin, mycosubtilin shows a distinct self-
assembly motif – extended nanotapes based on bilayers of lipo-
peptide molecules.30 This difference may be due to branching in
the lipid chains of mycosubtilin and/or due to conformational
differences in the cyclic peptide headgroup, although plipastatin
also includes backbone and side-chain aromatic units.
The critical micelle concentration of iturin A (Fig. 7c) was
determined by fluorescence assays using the intrinsic fluores-
cence of the D-tyrosyl residue (which is common to all iturins10a)
leading to a value of 25–40 mM in water.10a,42 The distribution of
conformers was found to be influenced by the cmc. The inter-
action of the lipopeptide with model (egg phosphatidylcholine)
vesicles was investigated: above the cmc, fluorescence revealed
self-association of iturin A inside the lipid membranes, an effect
not observed below the cmc.42 The micelle size and aggregation
number have been estimated.25 Far above the cmc, TEM images
suggest the presence of vesicles and an interdigitated bilayer
structure was proposed for the vesicle walls.43 Iturin A has been
shown to form potassium ion-conducting channels in lipid
bilayers.10a,44
Surfactin is able to permeabilize lipid membranes,38,45 and
it forms ion channels in planar lipid bilayer membranes.46 The
interaction of surfactin with POPC (1-palmitoyl-2-oleoyl-sn-
glycero-3-phosphocholine) vesicles has been investigated via
isothermal titration calorimetry and this has been correlated
to vesicle lysis probed by calcein fluorescence.47 Detergent-like
permeabilization eﬀects were observed on increasing concen-
tration even below the cmc (in the range 7.5 mM to 10 mM
depending on buﬀer38,45) although complete solubilisation
and the formation of mixed micelles occurs at the cmc.45,47
The study by Carillo et al. suggests that membranes are permea-
bilized by dimers of surfactin.45
Surfactin has a wide range of demonstrated activities,
including antifungal and antibiotic properties.9b,10b,c,d For the
latter, a pore-formation mechanism was proposed based on
permeabilization studies (using carboxyfluorescein as a fluores-
cent probe) using model lipid membranes.45 A range of other
Fig. 8 Molecular structures of lipopeptides produced by Pseudomonas
species. (a) Amphisin35 (b) syringomycin,36 (c) tolaasin I.37
Fig. 9 Relationship between the water/phospholipid partition coeﬃcient
K and the cmc for surfactin compared to several types of non-ionic and
ionic surfactant. CnEOm are alkyl ethyoxylate non-ionic surfactants,
CnMalt, CnGluc and CnThiogluc are alkyl maltosides, glucosides or thio-
glucosides, TX denotes triton ethylene oxide-based non-ionic surfactants,
CHAPS is a steroid, D7PC is diheptanoylphosphatidylcholine, and FOSMEA
is dodecyl phospho-n-methylethanolamine.38 The line corresponds to
K  cmc = 1. An oﬀset from the diagonal to lower K values indicates
strong membrane destabilization by the respective compound.
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very useful activities have been reported9b,10c,d,48 including
antiviral and antitumor properties and eﬀectiveness as an
anti-mycoplasma treatment. Surfactin has been shown to sup-
press inflammatory responses through inhibition of phospho-
lipase A2.
49 It is able to suppress biofilm formation by bacteria
such as Salmonella enterica and this was examined in PVC
plates as well as urethral catheters, pointing to relevance to
applications in healthcare.50 Surfactin C can enhance plasminogen
activation, and enhance fibrinolysis in vivo.51 This thrombolytic
activity is relevant to conditions involving blood clotting including
myocardial and pulmonary disorders. Linear analogues of surfac-
tin have been shown to have reduced haemolytic activity compared
to native cyclic variants. They were also observed to protect against
lytic (Triton) surfactant-induced haemolysis.52 This was correlated
to micellization, i.e. there is evidence for a relationship between
self-assembly and bioactivity from this study. Twomechanisms for
this were proposed – (i) the formation of mixedmicelles of the lytic
surfactant and the protective surfactin derivative, (ii) differences in
the insertion of the two surfactants into the cell membrane.52
It has been reported that lichenysin (Fig. 7a) has a much
lower cmc than surfactin (22 mM vs. 220 mM in 5 mM Tris
buﬀer) and is also a better chelator of Mg2+ and Ca2+ ions.27b
As noted above, the cmc of surfactin is very low in water and
other buﬀers,38,45 and in fact the value 220 mM for surfactin
seems too large compared to those reported previously (also in
Tris buﬀer).
Immune response lipopeptides
A series of lipopeptides that act as Toll-like receptor (TLR)
agonists have been developed, with important applications in
the treatment of infectious diseases. TLRs are transmembrane
proteins with a key role in the immune system and as such are
important therapeutic targets to treat infections.53 A list of
TLR targeting immuno-stimulatory agents being developed in
animal models to treat various viral and bacterial infections is
available.54 The toll-like receptor domains have been studied
by X-ray crystallography and, upon binding to PamnCSK4 lipo-
peptides (vide infra) reveal remarkable horse-shoe structures
resembling partial b-barrels (Fig. 10).55 The lipopeptide is
bound to the outer surface of the complex.
Pam3Cys lipopeptides (Fig. 11) are synthetic versions of the
N-terminal sequence of the principal lipoprotein of E. coli, also
known as Braun’s lipoprotein,57 that is abundant in the cell wall
of Gram-negative bacteria.58 Pam3Cys-based lipopeptides are able
to stimulate cytotoxic T lymphocyte (CTL) responses against
influenza virus-infected cells (when linked to influenza nucleo-
protein viral peptides).59 A related lipopeptide (Pam3CysSerSer
linked to a foot-and-mouth disease virus protein sequence) is
able to stimulate antibodies against foot-and-mouth disease.60
Pam3CysSerSer is able to mediate attachment to the cell
membrane, internalization into the cytoplasm and to activate
macrophages to secrete cytokines.59 As shown in Fig. 10,
Pam3CSK4 binding leads to an m-shaped heterodimer of the
TLR1 and TLR2 ectodomains, not observed for Pam2CSK4.
56
A similar crystal structure is reported for Pam2CSK4 bound to
the TLR2/TLR6 heterodimer.55
The Pam2Cys homologue of Pam3Cys lipopeptides has been
shown to correspond to the lipid moiety of macrophage-
activating lipopeptide 2 from mycoplasma.61 The presence of
only two lipid chains in Pam2Cys lipopeptides along with a
free amino group leads to improved water solubility. MALP-2,
where MALP stands for macrophage-activating lipopeptide, was
developed based on this lipopeptide with an attached GNNDES-
NISFKEK sequence (Fig. 12).61a,62 This lipopeptide is potent
in stimulating macrophages or monocytes at pM concentra-
tions.62 MALP-2 activates epithelial cells through TLR6 and
TLR2, but not TLR1 and TLR2.63 Indeed, TLR2 and TLR6
respond exclusively to lipopeptides possessing a diacylglycerol
group.64 Pam3CSK4 is recognised by TLR1 and TLR6 and does
not require TLR2.63,64b In addition, the R stereoisomer of
MALP-2 and Pam2CSK4 and Pam3CSK4 are more active than
the respective S stereoisomer. Together, these results indicates
the important role of the chirality of the central carbon in the
diacylglycerol group in TLR recognition.64b The role of specific
functional groups at the C terminus in the TLR2 activity of
Pam2Cys was examined which showed that a variant containing
a 1,3-dihydroxypropyl moiety showed higher activity than the
1,2-dihydroxypropyl derivative.3b Pam2Cys has been incorpo-
rated in other compounds, for instance a PEGylated analogue
was prepared to examine the eﬀect on influenza immunity
when administered without antigen.65 Attachment of synthetic
branched peptides rich in terminal arginine or glutamic acid
residues to Pam2Cys leads to enhanced protein immunogenicity
Fig. 10 Two views of X-ray crystal structure for the TLR1/TLR2 complex
bound by Pam3CSK4 (pdb file 2Z7X).
56 The right-hand image shows
the location of the bound lipopeptide molecule (represented as yellow
spheres).
Fig. 11 Scheme of generic Pam3Cys-based lipopeptide structure where R
indicates a peptide sequence.
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due to binding of charged protein (BSA as model agonist) to
the oppositely charged branched lipopeptide derivative.66 The
immune response was studied using influenza infected mice.
Immunocontraceptive vaccines have been developed, incor-
porating a peptide sequence EHWSYGLRPG from luteinizing
hormone-releasing hormone (LHRH).58 Lipopeptides incor-
porating LHRH are able to stimulate antibodies against this
‘‘self’’ hormone, leading to sterilization in a female mouse
model. Lipopeptides were synthesized based around Pam3Cys
and Pam2Cys templates incorporating the LHRH sequence
which incorporates one or more epitopes for B cells (denoted
[B]) as well as the CD4+ T cell epitope GALNNRFQIKGVELKS
(denoted [T]) from the L chain of influenza virus hemagglutinin.58
Lipopeptides with diﬀerent architectures were examined,
branched lipopeptides with [T] and [B] attached peripherally,
such as [T]-Lys-Pam2Cys-Ser-Ser-[B] induced a higher antibody
titer than that observed for linear lipopeptides with [T]–[B] at
the C terminus. In general, Pam2Cys-containing lipopeptides
were stated to be better immunogens that Pam3Cys ones.
58 It
has recently been shown that monoacyl PamCys lipopeptides
may be conveniently prepared via direct thiol–ene coupling,
enabling to the preparation of self-adjuvating antigenic lipo-
peptides with TLR2 agonist activity.67 A truncated sequence
from a cytomegalovirus (CMV) protein was used a model
epitope as it is able to stimulate CD8+ cytotoxic T-cells.
Lipopeptide-based vaccines have been developed to treat
several diseases including HIV,68 hepatitis B69 and HPV
(human papilloma virus)70 infections (HPV is also implicated
in several types of cancer including cervical cancer).
We recently investigated the self-assembly properties of three
PamnCSK4 lipopeptides (n = 1–3) (Fig. 13).71 A remarkable
dependence of morphology on the number of attached hexadecyl
lipid chains was found, with spherical micelle structures for
mono- and di-lipidated structures, but flexible wormlike micelles
for the homologue containing three lipid chains. Images
from cryogenic transmission electron microscopy (cryo-TEM)
are shown in Fig. 14. The self-assembled structure was also
confirmed by in situ small-angle X-ray scattering (SAXS) which
enables the dimensions of the nanostructures to be determined.
To investigate the thermal stability of the secondary structures,
and the possible role of lipid chain melting, we performed
temperature-dependent CD measurements. Neither PamCSK4
nor Pam2CSK4 show any significant change in the disordered
conformation in the temperature range 20–60 1C which covers
palmitoyl lipid chain melting temperatures, i.e. the lipid chain
melting transition previously observed for palmitoyl lipopeptides.72
In contrast, Pam3CSK4 exhibits a discontinuity in spectra between
30 1C and 40 1C, from a b-sheet conformation at lower temperature
to disordered at high temperature. This transition is partially
reversible. We associate this transition with the lipid chain melting
transition within the tri-palmitoyl chain lipopeptide. The transition
from the lipid gel to sol state (at around 40 1C) has previously been
shown to change the nanostructure of self-assemblies (twisted
ribbons or tapes) of gemini C16 surfactants.
73 We suggested that
the distinct modes of assembly may have an important influence
on the bioactivity of this class of lipopeptide. Interestingly, SAXS on
more concentrated samples (5 wt% lipopeptide) indicates that
Pam2CSK4 and Pam3CSK4 form complex cubic structures.
74 In the
same study, a lipolanthionine peptide (2R,6R)-Pam3LanHdaSer(Lys)4-
NH2 [Lan: lanthionine, Hda: hexadecanoic acid] was found to form
a lamellar phase (this lipopeptide in contrast to the PamnCSK4
compounds exhibits an inhibitory effect on activation of human
macrophages).74 We are currently investigating the lyotropic poly-
morphism of PamnCSK4 compounds in more detail.
The French National Agency for AIDS research (ANRS) has
developed a series of HIV-lipopeptides as part of a strategy to
Fig. 12 Molecular structure of MALP-2.61b
Fig. 13 Structure of PamnCSK4 lipopeptides. (a) PamCSK4, (b) Pam2CSK4,
(c) Pam3CSK4.
71
Fig. 14 Cryo-TEM images obtained for 2 wt% solutions. (a) PamCSK,
(b) Pam2CSK4, (c) Pam3CSK4. Enlarged images are shown at top in
(a) and (b) and to the right in (c).71
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create vaccines based on an induced CTL response.68 A list of
typical structures is provided in Table 1. This builds on the use
of simian immunodeficiency virus (SIV) as a model for vaccina-
tion using related lipopeptides (based on peptide sequences
from the SIV NEF or GAG proteins) that induce a CTL
response.75 To our knowledge, the self-assembly properties of
these compounds has yet to be investigated.
A lipopeptide (termed ‘‘Theradigm’’) used to create a vaccine
against chronic hepatitis B virus (HBV) comprises a peptide
sequence from a CTL linked to a T-helper peptide epitope
TetTox and two palmitoyl lipid chains (Fig. 15).69 CTLs are able
to recognise small 8–10 residue antigenic peptides. To our
knowledge, the self-assembly behaviour of this lipopeptide
has not yet been examined.
A lipopeptide with activity against HPV is C16-KSSTLGIVCPI
which contains the TLGIVCPI peptide sequence associated with
the E7 gene of HPV-16 as well as a hydrophilic KSS linker.70 The
lipopeptide was shown to have activity in generating cellular
immune responses in women with cervical cancer. A lipopeptide-
based vaccine treatment for hepatitis C has also been trialled
based on peptide sequences conjugated to the Pam2Cys
lipopeptide.76
Lipopeptides for applications in
cosmetics
We recently showed that the commercially available lipopeptide
Matrixylt (C16-KTTKS) undergoes self-assembly in aqueous
solution. This lipopeptide is used in skincare applications as
an antiwrinkle activity is suggested.4,77 The peptide headgroup
KTTKS is a sequence taken from a study on minimal Pro-collagen
peptide sequences able to stimulate collagen and fibronectin
production in fibroblasts.78
At neutral pH and below the lipid chain melting tempera-
ture, highly extended nanotape structures are observed, as
shown in Fig. 16.
We showed that the bilayer nanotape self-assembled structure
of C16-KTTKS is stable in the pH range 3–7 at room temperature,
although there was evidence for twisting of the tapes at pH 4,
but not pH 3 or pH 7.79 However, reduction of pH (to pH 2)79
or increase of temperature (above the lipid chain melting tem-
perature, around 35 1C dependent on concentration)80 leads to
the formation of spherical micelles. This is accompanied by a
loss of b-sheet secondary structure, as revealed by circular
dichroism spectroscopy and X-ray diffraction.79 Although very
low pH is not relevant to the application of the compound in
skincare (the pH of skin is around 4–6 although diseased skin
can have lower pH), the lipid chain melting temperature is close
to core body temperature although again the bilayer structure is
expected to be stable near the surface of the skin in the stratum
corneum.
This lipopeptide is able to stimulate collagen production by
fibroblasts (dermal and corneal) in a dose-dependent manner
close to the measured in DMEM media cac = 0.0055 wt%, as
shown by the results from a Sirius red assay for type I collagen
shown in Fig. 17.81 Since C16-KTTKS causes a slight decrease in
cell number following initial cell seeding, the collagen produc-
tion per cell increases more than the total collagen (Fig. 17).
This study was the first systematic in vitro study on the
collagen-stimulating properties of C16-KTTKS in the peer-
reviewed literature.
We also examined the self-assembly in water of related lipo-
peptides of interest in skincare applications, C16-GHK and C16-KT
as well as a commercial sample of C16-KTTKS (with higher
polydispersity than the 95%+ purity grade sample used in our
earlier studies).82 The KT peptide is a fragment of KTTKS while
GHK is a copper-chelating peptide with a collagen-stimulating
Table 1 Structures of HIV-lipopeptides developed by the ANRS study team. NEF, GAG and ENV are HIV-1 proteins. From Pialoux et al.68a
Lipo-peptide Long peptide Sequence MW No. AA
L-N1 N1 (a.a. NEF66–97) VGFPVTPQVPLRPMTYKAAVDLSHFLKEKGGLK(Pam) 3862.8 32(+1)
L-N2 N2 (a.a. NEF 117–147) TQGYFPDWQNYTPGPGVRYPLTFGWCYKLVPK(Pam) 4017.8 31(+1)
L-N3 N3 (a.a. NEF182–205) EWRFDSRLAFHHVARELHPEYFKNK(Pam) 3451.1 24(+1)
L-G1 G1 (a.a. GAG183–214) DLNTMLNTVGGHQAAMQMLKETINEEAAEWDRK(Pam) 3983.7 32(+1)
L-G2 G2 (a.a. GAG253–284) NPPIPVGEIYKRWIILGLNKIVRMYSPTSILDK(Pam) 4063.1 32(+1)
L-E E (a.a. ENV303–335) TRPNNNTRKSIHIGPGRAFYATGEIIGDIRQAHK(Pam) 4027.7 33(+1)
Fig. 15 Structure of theradigm lipopeptide.69
Fig. 16 Fibrillar superstructure of peptide amphiphile Matrixyl.72 (a) Confocal
optical microscopy image (fluorescent labelling with rhodamine B, 0.014 wt%
Matrixyl in water), (b) apple green birefringence observed by polarized optical
microscopy upon staining with Congo red, (c) diﬀerential optical microscopy
image (1 mg ml1 = 0.1 wt%).
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activity, involved in wound healing.83 All three lipopeptides
showed similar cac values (although the transition is not as sharp
as that observed for higher purity lipopeptides) and also had the
common feature in SAXS of lamellar reflections indicating bilayer-
based aggregates. However, TEM showed that C16-GHK and
C16-KT form small crystallite structures whereas C16-KTTKS forms
extended nanotapes. This latter material exhibits other ‘‘amyloid-
like’’ aggregate features, including the uptake of the dye Congo
red and a cross-b fibre X-ray diﬀraction pattern.82
Summary and future directions
This review has considered the bioactivity and self-assembly of
three classes of lipopeptide (i) bacterially-expressed cyclic lipo-
peptides with major applications in practice as antibacterial
and antifungal agents, (ii) linear toll-like receptor agonist
lipopeptides with activity in immune therapies and (iii) several
linear bio-derived lipopeptides with applications in skincare,
in particular one with a collagen-stimulating activity (trade-
name Matrixylt). In classes (ii) and (iii) recent work using
cryo-TEM and SAXS has established the self-assembled nano-
structure which is micelles or bilayer tapes, depending on the
nature of the lipopeptide (in particular the number of lipid
chains for the PamnCSK4 lipopeptides) as well as the self-
assembly conditions (temperature, pH etc.). There are some
studies on self-assembly of class (i) bacterially expressed lipo-
peptides with a cyclic peptide headgroup as cited above, but
in many cases this has not yet been examined. Clearly, this is
a fascinating direction for future research.
One key question concerns the relationship, if any, between
self-assembly and bioactivity. This is a complicated question for
a number of reasons. Firstly, self-assembly is often concentration-
dependent and decoupling the eﬀect of concentration on bio-
activity from the self-assembly process may be diﬃcult. This may
be circumvented by, for example, cross-linking self-assembled
structures to trap a particular thermodynamic state. This itself
may not be straightforward as the cross-linking process will
influence the self-assembled structure and potentially have an
impact on bioactivity. Second, it is not in general straightforward
to probe interactions between the substrate andmolecules and/or
aggregate without perturbing the molecule-aggregate equili-
brium, i.e. the self-assembly process, which is expected to be a
closed process. There are likely to be cases where self-assembled
structures themselves impart bioactivity – this is implied inmuch
work on synthetic lipopeptides where lipopeptide assemblies
present bioactive motifs at high density.84 This is also expected
to be a significant effect for Matrixylt where the extended fibrils
may provide a scaffold to enhance the collagen-stimulating
activity of the peptide and/or provide a ‘‘filler’’ for anti-wrinkle
skincare applications. It also seems likely to be the case that the
aggregation of bacterially-expressed lipopeptides is important in
stimulating or overcoming a host immune response. In other
cases there may be no direct relationship between self-assembly
and bioactivity (this will certainly be the case where bioactivity
is observed at very low concentration below any cmc or cac).
There may just be an indirect relationship in the sense that
amphiphilicity is important to bioactivity (e.g. compatibility
with the cell membrane) and the fact that this amphiphilicity
in turn leads to self-assembly at high concentration. In cases
such as the TLR agonist lipopeptides, crystal structures sug-
gest binding sites for unaggregated molecules and the role of
aggregate structures (if any) is not clear. The presence of
possible oligomeric species on or off the aggregation pathway
is a further complicating factor.
Moving forward, an interesting question is whether any
general rules of self-assembly can be established for the large
class of bacterially expressed lipopeptide, relating properties of
the molecule (charge, shape) to aggregation propensity, self-
assembled structure etc. In contrast to lipids, where models
such as the surfactant packing parameter or interfacial geo-
metry can be used to give guidance on the formation of self-
assembled structures for a given molecule at a particular
concentration,85 such models have yet to be developed for
lipopeptides. This in part may reflect the complexity of inter-
molecular interactions involving both lipid chains and peptide
headgroups. In the latter case, electrostatic, aromatic p-stacking
and hydrogen bonding interactions are of competing impor-
tance depending on the sequence and this is counterbalanced by
hydrophobic interactions of the lipid chains.
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Fig. 17 Collagen assay results showing the stimulation of human fibro-
blasts by C16-KTTKS.
81 (a) and (b) Human corneal fibroblasts, (c) and (d)
human dermal fibroblasts. Left, total amount of collagen deposited by cells
and right, total amount of collagen produced per cell (n = 3, *P r 0.005,
**P r 0.01 and ***P r 0.001).
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